DRI cell therapy for Glioblastoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Glioblastoma+2 More
DRI cell therapy - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing an experimental cell therapy to see if it is safe to give to patients with newly diagnosed glioblastoma multiforme, in combination with the standard treatment of temozolomide.

Eligible Conditions
  • Glioblastoma
  • Adult Brain Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Glioblastoma

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Through study completion, on average one year

12 weeks
Primary: Highest safe dose frequency or maximally planned dose, if no dose-limiting toxicity observed.
Through study completion, on average one year
Assessment of biological activity
Overall survival
Time to progression

Trial Safety

Safety Progress

1 of 3

Other trials for Glioblastoma

Trial Design

1 Treatment Group

DRI cell therapy
1 of 1
Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: DRI cell therapy · No Placebo Group · Phase 1

DRI cell therapy
Biological
Experimental Group · 1 Intervention: DRI cell therapy · Intervention Types: Biological

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, on average one year

Who is running the clinical trial?

In8bio Inc.Industry Sponsor
1 Previous Clinical Trials
38 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,419 Previous Clinical Trials
2,217,653 Total Patients Enrolled
9 Trials studying Glioblastoma
220 Patients Enrolled for Glioblastoma
Louis B Nabors, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
3 Previous Clinical Trials
73 Total Patients Enrolled
2 Trials studying Glioblastoma
64 Patients Enrolled for Glioblastoma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Hgb greater than or equal to 9.0 g/dL.
This study is evaluating whether a γδ T cell-based immunotherapy may help treat patients with non-Hodgkin lymphoma.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: October 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.